GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS for Diffuse large b-cell lymphoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 36 adverse event reports in the FDA FAERS database where GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS was used for Diffuse large b-cell lymphoma.
Most Reported Side Effects for GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 28 | 32.2% | 0 | 1 |
| Lymphoma | 17 | 19.5% | 0 | 0 |
| Cytokine release syndrome | 16 | 18.4% | 5 | 8 |
| Off label use | 14 | 16.1% | 3 | 2 |
| Neutropenia | 9 | 10.3% | 1 | 1 |
| Plasma cell myeloma refractory | 9 | 10.3% | 0 | 0 |
| Pyrexia | 8 | 9.2% | 0 | 2 |
| Atrial fibrillation | 5 | 5.8% | 0 | 0 |
| Covid-19 | 5 | 5.8% | 4 | 4 |
| Death | 5 | 5.8% | 5 | 3 |
| Malignant neoplasm progression | 5 | 5.8% | 0 | 0 |
Other Indications for GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS
Other Drugs Used for Diffuse large b-cell lymphoma
RITUXIMAB (22,275)
CYCLOPHOSPHAMIDE (16,598)
DOXORUBICIN (15,213)
VINCRISTINE (14,922)
PREDNISONE (11,266)
LENALIDOMIDE (7,858)
ETOPOSIDE (4,698)
PREDNISOLONE (4,086)
CYTARABINE (3,857)
DEXAMETHASONE (3,696)